| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H32N2O5 |
| Molecular Weight | 428.5213 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1OC)C(=O)N(CCCN(C)CCC3=CC(OC)=C(OC)C=C3)C2
InChI
InChIKey=UUMGNNQOCVDZDG-UHFFFAOYSA-N
InChI=1S/C24H32N2O5/c1-25(12-9-17-7-8-20(28-2)21(13-17)29-3)10-6-11-26-16-18-14-22(30-4)23(31-5)15-19(18)24(26)27/h7-8,13-15H,6,9-12,16H2,1-5H3
| Molecular Formula | C24H32N2O5 |
| Molecular Weight | 428.5213 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Falipamil (AQ-A 39), a bradycardiac agent is a calcium channel antagonist. Falipamil can be used to normalize sinus rate in patients with sinus tachycardia of various origin, particularly in intensive care, in acute ischemic heart disease, in anesthesia, and in surgery cases. Falipamil development has been discontinued.
